Xencor Inc. (XNCR), a clinical-stage biopharmaceutical company, will report financial results for the fourth quarter and full year 2023 after the market closes on Tuesday, February 27, 2024.
The same day, the company will furnish both a corporate update and a clinical update of its lead investigational drug Vudalimab in metastatic castration-resistant prostate cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com